Azilsartan Medoxomil Potassium 1417576-00-1

98% up by HPLC, DMF, WC

Product categories

New Products

Product Details

Product Information

Product name	Azilsartan Medoxomil Potassium； (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-oxo-3-((2’-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1’-biphenyl]-4-yl)methyl)-2,3-dihydro-1H-benzo[d]imidazole-4-carboxylate
CAS No.	1417576-00-1
Molecular Formula	C28H20N4O8
Molecular Weight	540.489
Quality Standard	98% up by HPLC
Appearance	White or almost white crystalline powder

COA

ANALYSIS	SPECIFICATION	RESULTS
Appearance	White or almost white crystalline powder	White crystalline powder
Solubility	Practically insoluble in water	Conforms
Identification	The retention time of the main peak should be consistent with the RS	Conforms
	The infrared absorption spectrum is concordant with that of RS	Conforms
	It gives the reaction of potassium(2).	Positive
Related substances	Impurity C ≤ 0.15%	ND
	Impurity A ≤ 1.5%	0.2%
	Unspecified impurities ≤ 0.10%	0.04%
	Total impurities ≤ 2.0%	0.4%
2-Ethylhexanoic acid	≤0. 5%	0.20%
Residual solvents	Ethanol ≤ 0.5%	ND
	Acetone ≤ 0.5%	0.01%
	Dichloromethane ≤ 0.06%	ND
	Tert-Butylmethyl ether ≤ 0.5%	0.10%
	Tetrahydrofuran ≤ 0.072%	ND
	n-Heptane ≤ 0.5%	ND
	Butyl acetate ≤ 0.5%	ND
Water	≤ 0.5%	0.09%
Heavy metals	≤ 20ppm	Conforms
Assay	≤98.0% - 102.0%(anhydrous substance)	99.7%
Conclusion	The sample complies with the Requirements of In House Specifications.

Usage

Compared to traditional sartan antihypertensive drugs, Azilsartan Medoxomil Potassium, with its unique oxadiazole ring structure, exhibits an affinity for angiotensin II receptors that is increased by over 10,000 times. Additionally, it binds more tightly to the receptor and dissociates more slowly, thereby exerting a potent, stable, and long-lasting antihypertensive effect. Furthermore, Azilsartan Medoxomil Potassium contains a unique pH modifier, which makes it unaffected by gastric acid upon oral administration, effectively enhancing drug stability and solubility.

While effectively controlling blood pressure, Azilsartan Medoxomil Potassium also offers cardiovascular and renal protective effects. Clinical studies have shown that, in addition to having significantly better antihypertensive efficacy than valsartan and olmesartan, Azilsartan Medoxomil Potassium also outperforms valsartan and olmesartan in reversing cardiac hypertrophy, stabilizing atherosclerotic plaques, resisting myocardial fibrosis, improving insulin resistance, reducing urine protein, and protecting the kidneys.